Mantle Cell Lymphoma
Mantle Cell Lymphoma
The latest news, research, and perspectives in mantle cell lymphoma (MCL). In MCL, a malignant B lymphocyte in the outer edge, or mantle zone, of a lymph node follicle grows uncontrollably, resulting in the accumulation of lymphoma cells.
Advertisement
Blood Cancer TalksChronic Lymphocytic Leukemia | January 31, 2025
David Russler-Germain, MD, PhD, joins the hosts of “Blood Cancer Talks” to highlight research in lymphoma and CLL.
Listen Now
Andrew MorenoT-Cell Lymphoma | January 30, 2025
Therapy also in development for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.
Andrew MorenoAggressive B-Cell Lymphoma | January 29, 2025
The single-slide test helps clinicians differentiate more than 60 subtypes of these diseases from normal immune response.
Blood Cancers Today Staff WritersMantle Cell Lymphoma | January 27, 2025
Researchers are launching a new clinical trial that will evaluate the combination of glofitamab with pirtobrutinib in MCL.
Andrew MorenoTransplantation & Cellular Therapy | January 23, 2025
The therapies are under development for EBV-positive PTLD, non-Hodgkin lymphoma, and systemic lupus erythematosus.
Melissa BadamoMantle Cell Lymphoma | January 17, 2025
Acalabrutinib was previously granted priority review in October 2024 based on results from the phase 3 ECHO trial.
Advertisement
Nichole TuckerFollicular Lymphoma | January 13, 2025
Relmacabtagene autoleucel is an anti-CD19 chimeric antigen receptor T-cell product
Andrew MorenoAcute Lymphoblastic Leukemia | January 10, 2025
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
Nichole TuckerMantle Cell Lymphoma | January 9, 2025
The phase 1b study of CAR22 is ongoing, and investigators are currently looking to enroll more patients.
Xu Ji, PhD, MSPHVideo Insights | January 3, 2025
A database study has identified an association between disease stage at lymphoma diagnosis and time of Medicaid enrollment.
Nichole TuckerMantle Cell Lymphoma | December 20, 2024
Updated results from the phase 3 ECHO trial were presented at ASH 2024.
Julie GouldMantle Cell Lymphoma | December 20, 2024
Future research must focus on developing more effective therapies to address the unmet needs of this high-risk MCL.
Nichole TuckerFollicular Lymphoma | December 12, 2024
Results from the phase 1 ENABLE-1 study show complete responses comparable to commercial CAR Ts in B-cell NHL.
Nichole TuckerChronic Lymphocytic Leukemia | December 12, 2024
CTX112, a next-generation allogeneic CRISPR-Cas9–engineered showing encouraging results in B-cell malignancies.
Andrew MorenoMeeting News | December 9, 2024
The approach demonstrated safety and produced response in B-ALL, DLBCL, follicular lymphoma, and MCL.
Melissa BadamoTransplantation & Cellular Therapy | December 8, 2024
Acalabrutinib, umbralisib, and ublituximab treatment is effective in patients with de novo MCL, with a 100% CR rate.
Andrew MorenoMantle Cell Lymphoma | December 2, 2024
A team of researchers investigated this mechanism of therapy resistance specifically to CD19-directed CAR T-cell therapy.
Andrew MorenoPrint | October 2, 2024
The anti-CD19 autologous CAR-T-cell therapy was approved for use in adults with relapsed or refractory disease.
Andrew MorenoMantle Cell Lymphoma | August 23, 2024
The results from a phase I seamless design study are relevant especially to older patients and those with high-risk disease.
Melissa BadamoMantle Cell Lymphoma | July 31, 2024
The study compared treatment response based on prior systemic lines of therapy and prior BTK inhibition in patients with MCL.
Advertisement
Advertisement